Scopus Biopharma Net Income
| SCPS Stock | USD 0.0006 0.0002 50.00% |
As of the 30th of January, Scopus Biopharma has the Coefficient Of Variation of 719.36, variance of 221.89, and Risk Adjusted Performance of 0.1104. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Scopus Biopharma, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Scopus Biopharma, which can be compared to its competition. Please validate Scopus Biopharma market risk adjusted performance and treynor ratio to decide if Scopus Biopharma is priced more or less accurately, providing market reflects its prevalent price of 6.0E-4 per share. As Scopus Biopharma appears to be a penny stock we also recommend to double-check its jensen alpha numbers.
Scopus Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Scopus Biopharma's valuation are provided below:Scopus Biopharma does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Scopus |
Scopus Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Scopus Biopharma's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Scopus Biopharma.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Scopus Biopharma on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Scopus Biopharma or generate 0.0% return on investment in Scopus Biopharma over 90 days. Scopus Biopharma is related to or competes with Orphazyme A/S. Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics t... More
Scopus Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Scopus Biopharma's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Scopus Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1349 | |||
| Maximum Drawdown | 83.33 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 33.33 |
Scopus Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scopus Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Scopus Biopharma's standard deviation. In reality, there are many statistical measures that can use Scopus Biopharma historical prices to predict the future Scopus Biopharma's volatility.| Risk Adjusted Performance | 0.1104 | |||
| Jensen Alpha | 2.07 | |||
| Total Risk Alpha | 1.01 | |||
| Treynor Ratio | (12.97) |
Scopus Biopharma January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1104 | |||
| Market Risk Adjusted Performance | (12.96) | |||
| Mean Deviation | 7.49 | |||
| Coefficient Of Variation | 719.36 | |||
| Standard Deviation | 14.9 | |||
| Variance | 221.89 | |||
| Information Ratio | 0.1349 | |||
| Jensen Alpha | 2.07 | |||
| Total Risk Alpha | 1.01 | |||
| Treynor Ratio | (12.97) | |||
| Maximum Drawdown | 83.33 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 33.33 | |||
| Skewness | 1.23 | |||
| Kurtosis | 4.87 |
Scopus Biopharma Backtested Returns
Scopus Biopharma is out of control given 3 months investment horizon. Scopus Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.11, which indicates the firm had a 0.11 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-two different technical indicators, which can help you to evaluate if expected returns of 1.56% are justified by taking the suggested risk. Use Scopus Biopharma Risk Adjusted Performance of 0.1104, variance of 221.89, and Coefficient Of Variation of 719.36 to evaluate company specific risk that cannot be diversified away. Scopus Biopharma holds a performance score of 8 on a scale of zero to a hundred. The entity has a beta of -0.16, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Scopus Biopharma are expected to decrease at a much lower rate. During the bear market, Scopus Biopharma is likely to outperform the market. Use Scopus Biopharma total risk alpha, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to analyze future returns on Scopus Biopharma.
Auto-correlation | 0.01 |
Virtually no predictability
Scopus Biopharma has virtually no predictability. Overlapping area represents the amount of predictability between Scopus Biopharma time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Scopus Biopharma price movement. The serial correlation of 0.01 indicates that just 1.0% of current Scopus Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.01 | |
| Spearman Rank Test | 0.85 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Scopus Biopharma reported net income of (26.95 Million). This is 107.9% lower than that of the Healthcare sector and 138.48% lower than that of the Biotechnology industry. The net income for all United States stocks is 104.72% higher than that of the company.
Scopus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in net income category among its peers.
Scopus Fundamentals
| Return On Equity | -15.6 | |||
| Return On Asset | -4.61 | |||
| Current Valuation | 1.18 M | |||
| Shares Outstanding | 21.09 M | |||
| Shares Owned By Insiders | 50.66 % | |||
| Shares Owned By Institutions | 2.15 % | |||
| Number Of Shares Shorted | 23.77 K | |||
| Price To Book | 2.42 X | |||
| EBITDA | (26.18 M) | |||
| Net Income | (26.95 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 2.54 M | |||
| Debt To Equity | 0.61 % | |||
| Current Ratio | 0.31 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (11.42 M) | |||
| Short Ratio | 0.22 X | |||
| Earnings Per Share | (1.51) X | |||
| Target Price | 12.0 | |||
| Beta | 1.16 | |||
| Market Capitalization | 2.17 M | |||
| Total Asset | 8.19 M | |||
| Z Score | -9.9 | |||
| Net Asset | 8.19 M |
About Scopus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scopus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scopus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scopus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scopus OTC Stock Analysis
When running Scopus Biopharma's price analysis, check to measure Scopus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scopus Biopharma is operating at the current time. Most of Scopus Biopharma's value examination focuses on studying past and present price action to predict the probability of Scopus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scopus Biopharma's price. Additionally, you may evaluate how the addition of Scopus Biopharma to your portfolios can decrease your overall portfolio volatility.